298 related articles for article (PubMed ID: 30689631)
21. DNA Sensing via TLR-9 Constitutes a Major Innate Immunity Pathway Activated during Erythema Nodosum Leprosum.
Dias AA; Silva CO; Santos JP; Batista-Silva LR; Acosta CC; Fontes AN; Pinheiro RO; Lara FA; Machado AM; Nery JA; Sarno EN; Pereira GM; Pessolani MC
J Immunol; 2016 Sep; 197(5):1905-13. PubMed ID: 27474073
[TBL] [Abstract][Full Text] [Related]
22. IgG antibody subclasses, tumor necrosis factor and IFN-gamma levels in patients with type II lepra reaction on thalidomide treatment.
Partida-Sanchez S; Favila-Castillo L; Pedraza-Sanchez S; Gomez-Melgar M; Saul A; Estrada-Parra S; Estrada-Garcia I
Int Arch Allergy Immunol; 1998 May; 116(1):60-6. PubMed ID: 9623511
[TBL] [Abstract][Full Text] [Related]
23. Enhanced cell-mediated immune responses in erythema nodosum leprosum reactions of leprosy.
Rao TD; Rao PR
Int J Lepr Other Mycobact Dis; 1987 Mar; 55(1):36-41. PubMed ID: 3549939
[TBL] [Abstract][Full Text] [Related]
24. Changes in circulating antibody levels to the major phenolic glycolipid during erythema nodosum leprosum in leprosy patients.
Andreoli A; Brett SJ; Draper P; Payne SN; Rook GA
Int J Lepr Other Mycobact Dis; 1985 Jun; 53(2):211-7. PubMed ID: 3894538
[TBL] [Abstract][Full Text] [Related]
25. Serum levels of interferon-gamma, tumour necrosis factor-alpha, soluble interleukin-6R and soluble cell activation markers for monitoring response to treatment of leprosy reactions.
Iyer A; Hatta M; Usman R; Luiten S; Oskam L; Faber W; Geluk A; Das P
Clin Exp Immunol; 2007 Nov; 150(2):210-6. PubMed ID: 17937676
[TBL] [Abstract][Full Text] [Related]
26. Can baseline ML Flow test results predict leprosy reactions? An investigation in a cohort of patients enrolled in the uniform multidrug therapy clinical trial for leprosy patients in Brazil.
Hungria EM; Oliveira RM; Penna GO; Aderaldo LC; Pontes MA; Cruz R; Gonçalves HS; Penna ML; Kerr LR; Stefani MM; Bührer-Sékula S
Infect Dis Poverty; 2016 Dec; 5(1):110. PubMed ID: 27919284
[TBL] [Abstract][Full Text] [Related]
27. Solubilization of preformed immune complexes in sera of patients with type 1 and type 2 lepra reactions.
Chakrabarty AK; Kashyap A; Sehgal VN; Saha K
Int J Lepr Other Mycobact Dis; 1988 Dec; 56(4):559-65. PubMed ID: 3221112
[TBL] [Abstract][Full Text] [Related]
28. Regulatory T cells in erythema nodosum leprosum maintain anti-inflammatory function.
Negera E; Bobosha K; Aseffa A; Dockrell HM; Lockwood DNJ; Walker SL
PLoS Negl Trop Dis; 2022 Jul; 16(7):e0010641. PubMed ID: 35867720
[TBL] [Abstract][Full Text] [Related]
29. In Situ complement activation and T-cell immunity in leprosy spectrum: An immunohistological study on leprosy lesional skin.
Bahia El Idrissi N; Iyer AM; Ramaglia V; Rosa PS; Soares CT; Baas F; Das PK
PLoS One; 2017; 12(5):e0177815. PubMed ID: 28505186
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive evaluation of complement components in the course of type I (Lepra) and type II (ENL) reactions.
Sehgal VN; Sharma V; Sharma VK
Int J Dermatol; 1989; 28(1):32-5. PubMed ID: 2783924
[TBL] [Abstract][Full Text] [Related]
31. Sequential erythema nodosum leprosum and reversal reaction with similar lesional cytokine mRNA patterns in a borderline leprosy patient.
Moraes MO; Sampaio EP; Nery JA; Saraiva BC; Alvarenga FB; Sarno EN
Br J Dermatol; 2001 Jan; 144(1):175-81. PubMed ID: 11167702
[TBL] [Abstract][Full Text] [Related]
32. In vitro tumor necrosis factor production by mononuclear cells from lepromatous leprosy patients and from patients with erythema nodosum leprosum.
Santos DO; Suffys PN; Bonifácio K; Marques MA; Sarno EN
Clin Immunol Immunopathol; 1993 Jun; 67(3 Pt 1):199-203. PubMed ID: 8500267
[TBL] [Abstract][Full Text] [Related]
33. In vitro thalidomide does not interfere with the activation of complement by M. leprae.
Shannon EJ; Sandoval FG; Morales MJ
J Drugs Dermatol; 2011 Mar; 10(3):274-8. PubMed ID: 21369644
[TBL] [Abstract][Full Text] [Related]
34. Levels of IgG subclasses in active and inactive cases in the disease spectrum of leprosy.
Beuria MK; Parkash O; Joshi B; Mohanty KK; Katoch K; Sengupta U
Int Arch Allergy Immunol; 1998 Jan; 115(1):61-6. PubMed ID: 9430497
[TBL] [Abstract][Full Text] [Related]
35. Production of transforming growth factor-beta 1 (TGF-beta1) by blood monocytes from patients with different clinical forms of leprosy.
Goulart IM; Mineo JR; Foss NT
Clin Exp Immunol; 2000 Dec; 122(3):330-4. PubMed ID: 11122237
[TBL] [Abstract][Full Text] [Related]
36. Towards understanding the pathology of erythema nodosum leprosum.
Kahawita IP; Lockwood DN
Trans R Soc Trop Med Hyg; 2008 Apr; 102(4):329-37. PubMed ID: 18313706
[TBL] [Abstract][Full Text] [Related]
37. Risk factors for erythema nodosum leprosum.
Manandhar R; LeMaster JW; Roche PW
Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):270-8. PubMed ID: 10575406
[TBL] [Abstract][Full Text] [Related]
38. Complement C1q expression in Erythema nodosum leprosum.
Negera E; Walker SL; Lema T; Aseffa A; Lockwood DN; Dockrell HM
PLoS Negl Trop Dis; 2018 Mar; 12(3):e0006321. PubMed ID: 29499046
[TBL] [Abstract][Full Text] [Related]
39. T-cell regulation in Erythema Nodosum Leprosum.
Negera E; Walker SL; Bobosha K; Howe R; Aseffa A; Dockrell HM; Lockwood DN
PLoS Negl Trop Dis; 2017 Oct; 11(10):e0006001. PubMed ID: 28991896
[TBL] [Abstract][Full Text] [Related]
40. Clinical course of erythema nodosum leprosum: an 11-year cohort study in Hyderabad, India.
Pocaterra L; Jain S; Reddy R; Muzaffarullah S; Torres O; Suneetha S; Lockwood DN
Am J Trop Med Hyg; 2006 May; 74(5):868-79. PubMed ID: 16687695
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
